Susquehanna International Group, LLP Natera, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$97.75 - $129.67 $381,225 - $505,712	3,900 Added 4.77%	85,600 $10.9 Million
Q2 2024 Aug 15, 2024	BUY	$85.28 - $112.6 $4.31 Million - $5.69 Million	50,500 Added 161.86%	81,700 $8.85 Million
Q1 2024 May 07, 2024	SELL	$59.21 - $92.9 $1.94 Million - $3.05 Million	-32,800 Reduced 51.25%	31,200 $2.85 Million
Q4 2023 Feb 14, 2024	SELL	$37.55 - $62.64 $1.62 Million - $2.7 Million	-43,100 Reduced 40.24%	64,000 $4.01 Million
Q3 2023 Nov 14, 2023	SELL	$43.4 - $62.52 $73,780 - $106,284	-1,700 Reduced 1.56%	107,100 $4.74 Million
Q2 2023 Aug 11, 2023	BUY	$47.08 - $55.16 $1.67 Million - $1.95 Million	35,400 Added 48.23%	108,800 $5.29 Million
Q1 2023 May 16, 2023	BUY	$36.57 - $58.29 $2.2 Million - $3.51 Million	60,200 Added 456.06%	73,400 $4.08 Million
Q4 2022 Feb 14, 2023	SELL	$34.17 - $47.91 $1.72 Million - $2.41 Million	-50,200 Reduced 79.18%	13,200 $530,000
Q3 2022 Nov 14, 2022	SELL	$36.93 - $56.68 $77,553 - $119,028	-2,100 Reduced 3.21%	63,400 $2.78 Million

547

118M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.3B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.